Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Chemomab Therapeutics ( (CMMB) ) has provided an announcement.
Chemomab Therapeutics announced that its Annual General Meeting of Shareholders, originally scheduled for April 28, 2026 in Ramat Gan, Israel, was adjourned due to a lack of quorum. The meeting has been rescheduled for May 5, 2026 at the same time and location, with the previously filed proxy statement from March 20, 2026 continuing to govern the proposed resolutions and agenda items.
The adjournment underscores limited shareholder participation at the initially planned meeting, potentially signaling engagement challenges among Chemomab’s investor base. The company also noted that this Form 6-K filing, dated April 28, 2026 and signed by its chief financial officer, is incorporated by reference into its existing F-3 and S-8 registration statements, maintaining continuity for its U.S. securities offerings and employee equity plans.
The most recent analyst rating on (CMMB) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Chemomab Therapeutics stock, see the CMMB Stock Forecast page.
Spark’s Take on CMMB Stock
According to Spark, TipRanks’ AI Analyst, CMMB is a Neutral.
The score is primarily constrained by weak financial fundamentals (pre-revenue, ongoing losses, and negative free cash flow) and a technically weak price trend below major moving averages. Valuation contributes limited support due to the negative P/E and lack of dividend yield data.
To see Spark’s full report on CMMB stock, click here.
More about Chemomab Therapeutics
Chemomab Therapeutics Ltd. is an Israel-based biopharmaceutical company focused on developing novel therapies, typically targeting fibrotic and inflammatory diseases. The company is listed in the United States as a foreign private issuer and accesses U.S. capital markets through shelf registration statements to support its clinical and operational activities.
Average Trading Volume: 68,734
Technical Sentiment Signal: Sell
Current Market Cap: $11.58M
Learn more about CMMB stock on TipRanks’ Stock Analysis page.